Biosion, Inc.



Biosion is a biotech company focusing on the discovery and preclinical development of innovative biologicals for unmet medical needs.

Leveraging its proprietary H³ antibody platform and SynAb™ technology, Biosion is committed to develop antibody drug candidates with optimal specificity and mechanistic drug properties.

Biosion "SynNovation 100 program" with the goal to develop first-in-class or best-in-class antibody drug candidates to 100 critically reviewed drug targets.



With its cutting-edge technologies and robust antibody discovery platform, Biosion is committed to discover and develop world-class antibody drugs for the unmet medical needs.


About Us